FDA Approves Subcutaneous Starting Dose for Leqembi Iqlik, Bringing At-Home Initiation to Early Alzheimer's Treatment

Overview

The U.S. Food and Drug Administration has approved a subcutaneous starting dose for Leqembi Iqlik (lecanemab-irmb), letting patients with early Alzheimer’s disease begin anti-amyloid treatment with an at-home autoinjector instead of an intravenous infusion, according to Eisai and Biogen. The companies announced the approval of the supplemental Biologics License Application on July 13, 2026, roughly two months after the FDA had extended its review period, according to Eisai and Biogen.

What We Know

• The approved initiation regimen is 500 mg once weekly, delivered as two 250 mg injections, each administered in approximately 15 seconds via autoinjector, according to Eisai and Biogen.
• Leqembi Iqlik is indicated for adults with mild cognitive impairment or mild dementia due to Alzheimer’s disease, collectively termed early Alzheimer’s disease, according to Eisai and Biogen. BioSpace describes mild cognitive impairment as “the earliest symptomatic stage, characterized by subtle symptoms like forgetfulness and confusion.”
• Patients who complete initiation can move to maintenance dosing of 360 mg once weekly after 18 months of prior intravenous or subcutaneous treatment, according to Eisai and Biogen.
• Once-weekly subcutaneous administration achieved exposure equivalent to intravenous dosing, and 94% of patients and caregivers found the autoinjector easy to use, according to Eisai and Biogen.
• Clinical data presented at the Alzheimer’s Association International Conference (AAIC) 2026 found that once-weekly 500 mg subcutaneous dosing “demonstrated bioequivalence to the IV initiation regimen (10 mg/kg every two weeks), with an exposure ratio of 104% (90% confidence interval [CI]: 99.1%–109%)”. The same data found anti-drug antibodies in 1.4% of the subcutaneous group, with no neutralizing antibodies detected, according to Eisai and Biogen.
• Researchers reported: “Amyloid removal measured by amyloid PET, clinical efficacy measured by CDR-SB, and the incidence of ARIA-E were driven by lecanemab exposure rather than route of administration.” The same data showed patient satisfaction ranging from 75% to 97%, convenience ratings from 83% to 97%, and willingness to recommend the subcutaneous option from 92% to 100%.
• Leqembi’s known safety profile, republished alongside the approval, shows amyloid-related imaging abnormalities (ARIA) occurring in 21% of patients on the drug versus 9% on placebo overall, with ARIA-E at 13% versus 2% and ARIA-H at 17% versus 9%; symptomatic ARIA occurred in 3% of patients and serious symptoms in 0.7%, according to StockTitan. Patients who carry two copies of the ApoE ε4 gene showed ARIA rates of 45%, compared with 19% for single-copy carriers and 13% for noncarriers, per the same safety data.
• Eisai leads development and regulatory submissions for lecanemab while Biogen co-commercializes the drug, according to BioSpace. Swedish biotech BioArctic, Eisai’s original development partner on lecanemab, also announced the approval. BioArctic CEO Gunilla Osswald said: “This approval represents another important step forward in the treatment of Alzheimer’s disease. By providing a new administration option from the start of treatment, patients, caregivers and healthcare professionals gain greater flexibility in how therapy is delivered.”
• Leqembi Iqlik is expected to be available in the U.S. in late August 2026 through specialty pharmacy distribution, according to Eisai and Biogen.
• Howard Fillit, MD, Co-Founder and Chief Science Officer Emeritus of the Alzheimer’s Drug Discovery Foundation, said in the companies’ announcement: “The approval of LEQEMBI IQLIK for initiation dosing marks a new era of Alzheimer’s treatments. For the first time, patients and their care partners have meaningful choice in how anti-amyloid treatment is delivered.”
• In a separate statement, the Alzheimer’s Drug Discovery Foundation’s Interim Chief Science Officer, Laura Nisenbaum, PhD, said: “Subcutaneous approval is an important step toward the kind of scalable care model Alzheimer’s will need as the field moves from single-drug treatment toward combination therapies.” Nisenbaum added that at-home regimens “are only sustainable if each therapy can be given at home, which avoids compounding the burden on patients and caregivers.” ADDF Chief Executive Officer Isobel Coleman called the approval “an inflection point for Alzheimer’s treatment.”
• The foundation noted that 75% of the current Alzheimer’s drug pipeline is focused on non-amyloid pathways, and said it has awarded nearly $400 million to fund 792 Alzheimer’s drug development programs across 21 countries, according to the Alzheimer’s Drug Discovery Foundation. The foundation also noted that the subcutaneous injection takes approximately 15 seconds versus hour-long IV infusions, the same source shows.

What We Don’t Know

The companies have not disclosed a list price for the initiation-dose autoinjector ahead of its late-August launch. It is also not yet clear how quickly specialty pharmacies and insurers will move to cover the at-home starting regimen, or how uptake among newly diagnosed patients will compare with the existing intravenous pathway.

Why It Matters

Leqembi was already approved for at-home maintenance dosing, but until now every patient starting the drug needed recurring infusion-center visits during the initiation phase. Bringing the starting dose home removes that early bottleneck, which the Alzheimer’s Drug Discovery Foundation frames as groundwork for the multi-drug combination regimens it expects will define the next phase of Alzheimer’s care, according to the foundation’s statement.